QUEBEC PROVIDES GERD SUFFERERS WITH MUCH NEEDED RELIEF

RAMQ Provides Open Access to DEXILANT, the First and only Proton Pump Inhibitor (PPI) with a DUAL DELAYED RELEASE (DDR) Technology

MISSISSAUGA, ON, June 3, 2011 /CNW/ - Patients in Quebec living with GERD now have open access to a new treatment option that offers improved and sustained symptom relief, as the Régie de l'assurance maladie Quebec (RAMQ) adds DEXILANT (dexlansoprazole) to the provincial formulary.

DEXILANT is the first and only proton pump inhibitor (PPI) with a novel DUAL DELAYED RELEASE technology for the once-daily treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis and the maintenance of healed erosive esophagitis.

Quebec residents who qualify for Quebec's Public Prescription Drug Insurance Plan - those 65 and older, recipients of last-resort financial assistance and those who are not covered by private plans - are eligible.

GERD is a chronic condition that affects approximately one-third of the Canadian population and, if left untreated, can result in damage to the esophagus leading to ulcers and bleeding.1,2 Some of the most common symptoms associated with GERD include: regurgitation, sour taste in the mouth, pain or burning in the throat or chest, and awakening in the night due to heartburn. Symptoms can be triggered by foods, such as chocolate, fried/fatty foods, alcohol and coffee.1

It is estimated that GERD sufferers are absent from work 16 per cent of the year due to uncontrolled symptoms. In Canada, this represents 1.7 billion hours of lost productivity which amounts to $21 billion every year.1

"Takeda is dedicated to developing health care solutions that address the unmet medical needs of patients, and we are thrilled that Quebec has recognized the needs of GERD patients," says Paul Friel, General Manager and President, Takeda Canada, Inc. "By adding DEXILANT to the provincial formulary, the province is not only helping more patients gain access to this new treatment option, but helping these patients get back to living better lives."

About Takeda Canada, Inc.

Takeda Canada, Inc. is a division of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The Canadian headquarters was established in Mississauga, Ontario, in 2009. Takeda Canada, Inc. currently distributes Actos® for the treatment of type 2 diabetes, DEXILANT for the treatment of gastroesophageal reflux disease and ULORIC an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout. The company seeks to enhance the lives of Canadians by providing innovative new products for metabolic, cardiovascular, oncology, central nervous system, and other related conditions. Takeda is committed to striving toward better health for individuals and progress in medicine. To learn more about Takeda Canada, Inc. visit www.takedacanada.com.

______________________________________
1 Canadian Digestive Health Foundation. GERD. http://www.cdhf.ca/pdfs/fact-sheets/CDHF_FactSheet_GERD.pdf#zoom=100. Accessed December, 2010.
2 Canadian Society of Intestinal Research. GERD. http://www.badgut.org/information-centre/gerd.html Accessed December, 2010.


SOURCE Takeda Canada, Inc.

For further information:

Laurene Redding
Takeda Canada, Inc.
905-814-2329
laurene.redding@takedacanada.com

Profil de l'entreprise

Takeda Canada, Inc.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.